Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ikena Oncology Inc
(NQ:
IKNA
)
1.400
+0.065 (+4.87%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ikena Oncology Inc
< Previous
1
2
3
4
Next >
Ikena Oncology to Participate in Upcoming Investor Conferences
May 24, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Analyst Ratings for Ikena Oncology
May 16, 2023
Via
Benzinga
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
May 15, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology Announces $40 Million Underwritten Offering
May 15, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Credit Suisse Maintains Outperform Rating for Ikena Oncology: Here's What You Need To Know
March 15, 2023
Via
Benzinga
Ikena Oncology Earnings Perspective: Return On Capital Employed
March 15, 2023
Via
Benzinga
Ikena Oncology's Return On Capital Employed Insights
November 30, 2022
Via
Benzinga
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 20, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
April 17, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
March 07, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology: Q3 Earnings Insights
November 07, 2022
Ikena Oncology (NASDAQ:IKNA) reported its Q3 earnings results on Monday, November 7, 2022 at 08:05 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
March 06, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 14, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 27, 2022
Via
Benzinga
Ikena Oncology Appoints Owen Hughes as Board Chair
December 19, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
December 09, 2022
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
Via
Benzinga
Ikena Oncology Announces New Cancer Program, Shelves Early Asset For Colorectal Cancer
November 28, 2022
Ikena Oncology Inc (NASDAQ: IKNA) nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as its first development candidate in the RAS pathway.
Via
Benzinga
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
November 28, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
November 10, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 07, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 07, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
October 31, 2022
During Monday's session, 96 stocks hit new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 26, 2022
Gainers
Via
Benzinga
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
October 26, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
October 18, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
October 25, 2022
On Tuesday, 120 companies set new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.